New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.

Study suggests CD4+ T cells mediate these immune-related toxicities ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma. In 2021, the FDA approved idecabtagene vicleucel (ide ...

Many symptoms of multiple myeloma (MM) overlap with other conditions, including low back pain, diabetes, chronic kidney disease and arthritis. Renal insufficiency caused by MM can be difficult to ...

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple myeloma after treatment.

Multiple myeloma patients have a fivefold increased risk of infections compared to healthy controls, with sepsis and pneumonia being the most prevalent. The study found a 70% infection risk in MM ...

The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...

Trends in survival disparity following breast cancer diagnosis by health insurance coverage and race in the US. Yearly incidence of TLS in hospitalized patients with MM.

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...